-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
New Releases for the Year of the Horse! Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical Receives Concurrent Approval for Two Active Pharmaceutical Ingredients: Metoclopramide Hydrochloride and Metoclopramide
Category:
TIME：2026-03-10
On February 27, the active pharmaceutical ingredients metoclopramide hydrochloride and metoclopramide, developed by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, successfully had their registration status at the Center for Drug Evaluation of the National Medical Products Administration changed to “A,” thereby qualifying as APIs used in marketed dosage forms. Since the beginning of this year, the Group has received approval for a total of five new specialty API products.
According to available information, metoclopramide hydrochloride and metoclopramide are dopamine D2 receptor antagonists that also exhibit agonistic activity at serotonin 5-HT4 receptors, thereby promoting gastrointestinal motility. The primary indication for these agents is the control of emesis, and they are used to treat symptoms such as nausea, belching, gastric distension, and reflux esophagitis.
In recent years, the Group has anchored itself in both domestic and international markets, continuously deepening its integrated innovation strategy that combines active pharmaceutical ingredients (APIs) with finished dosage forms. It has driven the high-end development of injectables, the diversification of oral formulations, and the specialized advancement of APIs, gradually establishing a robust product portfolio spanning anti-infectives, antivirals, respiratory, neurological, renal, cardiovascular and cerebrovascular, gastrointestinal, anesthetic, and endocrine therapeutic areas. At the same time, leveraging process optimization and digital transformation, the Group has steadily strengthened its API quality and cost advantages, becoming a reliable partner for numerous formulation manufacturers. To date, the Group boasts 96 API products, including 54 under Guangxiang Pharmaceutical, thereby injecting strong momentum into the company’s innovative, high-quality growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
